Updates are available Correction dated 2026-01-23
Click to view Correction: https://doi.org/10.1038/s43856-026-01388-x
-
Authors
van Eijs, Mick J. M. https://orcid.org/0000-0002-9763-6704
van der Wal, M. Marlot https://orcid.org/0000-0003-4554-9059
Klotškova, Hedi-Britt https://orcid.org/0009-0000-3291-5000
Dautzenberg, Noël M. M.
Schuiveling, Mark https://orcid.org/0000-0002-2631-7271
Verheijden, Rik J. https://orcid.org/0000-0003-1966-1063
van Schaik, Fiona D. M.
Oldenburg, Bas
Nierkens, Stefan
,
van Wijk, Femke
Suijkerbuijk, Karijn P. M. https://orcid.org/0000-0003-3604-5430
van Wijk, Femke https://orcid.org/0000-0001-8343-1356
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (CA209-6JY)
- License Information
-
More Information
Article History
Received: 5 March 2025
Accepted: 25 September 2025
First Online: 18 November 2025
Change Date: 23 January 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43856-026-01388-x
Competing interests
: M.J.M.v.E., M.M.v.d.W., H.B.K., N.M.M.D., M.S., R.J.V., F.D.M.v.S., B.O., S.N.: none. K.P.M.S.: Consulting/advisory relationship: Abbvi,e, Sairopa. Research funding: TigaTx, Bristol Myers Squibb, Philips, Genmab, Pierre Fabre. Honoraria: Bristol Myers Squibb. All paid to institution. F.W.: has advisory relationships with Janssen and Takeda, and received research funding from Takeda, Galapagos, BMS, Sanofi, and Leo Pharma.
